Unlocking the healing power of Berberine: A promising aid for multiple sclerosis.
Berberine shows promise in preclinical MS models, but clinical trials are necessary to confirm its efficacy and safety in humans.
Where it sits
this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpusSummary and findings
This narrative review evaluates the potential of berberine (BBR) as a therapeutic candidate for multiple sclerosis (MS) by examining preclinical evidence from animal models. BBR has shown to reduce pro-inflammatory cytokines and promote remyelination in experimental autoimmune encephalomyelitis and cuprizone-induced demyelination models. The review highlights the need for clinical trials to validate these findings.
Abstract
Multiple sclerosis (MS) is a debilitating autoimmune disorder characterized by inflammatory demyelination and progressive neurodegeneration within the central nervous system (CNS). Despite advances in disease-modifying therapies (DMTs), current treatments primarily mitigate relapses and slow disease progression but fall short in comprehensively addressing cumulative disability or neurodegeneration. Berberine (BBR), a naturally occurring isoquinoline alkaloid, has emerged as a promising therapeutic candidate due to its potent immunomodulatory, anti-inflammatory, and neuroprotective properties. In this narrative review, we synthesize the molecular mechanisms underpinning BBR's effects on MS pathology and evaluate preclinical evidence from MS-relevant animal models. Studies in experimental autoimmune encephalomyelitis (EAE) -the primary MS model-and the cuprizone (CPZ) -induced demyelination model demonstrate that BBR (typically 5-300 mg/kg in preclinical protocols) reduces pro-inflammatory cytokines, modulates immune responses, and promotes remyelination-processes critical for counteracting MS-associated neurodegeneration. BBR modulates key signaling pathways, including JAK/STAT and SPHK1/S1P, which are pivotal in attenuating immune-mediated damage and preserving blood-brain barrier (BBB) integrity. Despite its therapeutic potential, challenges such as poor bioavailability and suboptimal pharmacokinetics have spurred investigations into advanced delivery systems. Nanoformulations, particularly BBR-loaded iron oxide nanoparticles (BBR-IONP), have shown superior efficacy in preclinical models by enhancing CNS delivery and improving remyelination outcomes. By highlighting BBR's multifaceted bioactivities, this review underscores its promise as a complementary or alternative approach to address unmet needs in MS management, while acknowledging the critical need for clinical trials to validate these preclinical findings.
Background
Multiple sclerosis (MS) is a severe autoimmune disorder affecting the central nervous system, leading to demyelination and neurodegeneration. Current treatments primarily focus on reducing relapses and slowing progression but do not fully address neurodegeneration or cumulative disability. This study explores berberine's potential as a therapeutic agent due to its immunomodulatory, anti-inflammatory, and neuroprotective properties, which could address these unmet needs.
Methods
This is a narrative review synthesizing preclinical evidence from MS-relevant animal models, specifically experimental autoimmune encephalomyelitis and cuprizone-induced demyelination models. Berberine was administered at doses ranging from 5 to 300 mg/kg in these models. The review evaluates berberine's impact on pro-inflammatory cytokines, immune response modulation, and remyelination.
Results
The review reports that berberine reduces pro-inflammatory cytokines and promotes remyelination in animal models of MS. It modulates key signaling pathways, such as JAK/STAT and SPHK1/S1P, which are crucial for reducing immune-mediated damage and maintaining blood-brain barrier integrity. Nanoformulations, such as berberine-loaded iron oxide nanoparticles, have shown enhanced efficacy in CNS delivery and remyelination outcomes.
Interpretation
While the preclinical findings suggest that berberine has potential therapeutic benefits for MS, these results are limited to animal models. The effect sizes and mechanisms observed in these studies need to be validated in human clinical trials to determine their clinical significance. The review highlights the challenges of berberine's bioavailability and pharmacokinetics, which may limit its practical application without advanced delivery systems.
Key findings
- BBR typically used at 5-300 mg/kg in preclinical protocols.
- BBR reduces pro-inflammatory cytokines in MS models.
- BBR modulates JAK/STAT and SPHK1/S1P signaling pathways.
- BBR-loaded iron oxide nanoparticles enhance CNS delivery.
- Nanoformulations improve remyelination outcomes in preclinical models.
Limitations
- Preclinical evidence only, no human data.
- Narrative review, not a systematic review or meta-analysis.
- Challenges with berberine's bioavailability and pharmacokinetics.
- Need for clinical trials to validate findings.